ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Oxaliplatin


Oxaliplatin Suppliers list
Company Name: Jiangsu Yew Pharmaceutical Co., Ltd.
Tel: +86-510-66865338 +86-189-2133-5032
Products Intro: Product Name:Oxaliplatin
Purity:98.5 Package:1KG;40000USD
Company Name: TianYuan Pharmaceutical CO.,LTD
Tel: +86-755-23284190 13684996853
Products Intro: Product Name:Oxaliplatin
Purity:98% Package:10g 100g 200g 500g 1kg 5kg per barrel
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: +86-0371-55170693 +86-19937530512
Products Intro: Product Name:TIANFUCHEM-- 61825-94-3 -- Oxaliplatin in stock
Purity:99% Package:25KG;5KG;1KG
Company Name: Hangzhou FandaChem Co.,Ltd.
Tel: +8615858145714
Products Intro: Product Name:oxaliplatin fandachem
Purity:As coa Package:As request Remarks:61825-94-3
Company Name: Guangzhou PI PI Biotech Inc
Tel: +86-020-81716320 +86-18371201331
Products Intro: Product Name:Oxaliplatin
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Remarks:(SP-4-2)-[(1R,2R)-Cyclohexane-1,2-diamine-κN,κN′][ethanedioato(2-)-κO1,κO2]platinum

Oxaliplatin manufacturers

  • Oxaliplatin
  • $0.00 / 25Kg/Drum
  • 2022-07-01
  • CAS:61825-94-3
  • Min. Order: 1Kg/Drum
  • Purity: 99%
  • Supply Ability: 5000KG
  • Oxaliplatin
  • $0.00 / 25KG
  • 2022-06-10
  • CAS:61825-94-3
  • Min. Order: 2KG
  • Purity: EP7.2
  • Supply Ability: 20tons
Oxaliplatin Basic information
Indications and Usage Mechanisms of Action Adverse Effects
Product Name:Oxaliplatin
Synonyms:[SP-4-2-(1R-TRANS)]-(1,2-CYCLOHEXANEDIAMINE-N,N')[ETHANEDIOATA(2-)-O,O']PLATINUM;OXALIPLATIN;trans-l-diaminocyclohexane oxalatoplatinum;(1,2-cyclohexanediamine-n,n’)(ethanedioato(2-)-o,o’)-platinu(sp-4-2-(1r-tr;oxalato(1r,2r-cyclohexanediammine)platinum(ii);oxalatoplatin;[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N,)[ethanedioato(2-)-O,O’Jplatinum;NSC-266046:Elocatin
Product Categories:Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Antineoplastic;Inhibitors;APIs;Amines;Heterocycles;chemical reaction,pharm,electronic,materials;PRAXILENE;API
Mol File:61825-94-3.mol
Oxaliplatin Structure
Oxaliplatin Chemical Properties
alpha +74.5-78.0 (D/20)(c=0.5,H2O)
storage temp. 2-8°C
solubility Slightly soluble in water, very slightly soluble in methanol, practically insoluble in anhydrous ethanol.
form solid
Water Solubility Soluble in water with heating and/or sonication
Merck 14,6912
Stability:Stable. Store cool. Incompatible with oxidizing agents.
CAS DataBase Reference61825-94-3
Safety Information
Hazard Codes Xn,Xi
Risk Statements 36/37/38-40-42/43
Safety Statements 26-36
WGK Germany 3
RTECS TP2275850
HazardClass 6.1(a)
PackingGroup II
HS Code 28439000
ToxicityLD50 intraperitoneal in mouse: 19800ug/kg
MSDS Information
SigmaAldrich English
Oxaliplatin Usage And Synthesis
Indications and UsageOxaliplatin, also called Eloxatin or Eloxatine, is a platinum derivative.
Used clinically to treat patients with metastatic colorectal cancer after failure of fluorouracil treatment, can be used alone or in combination with 5-fluorouracil. It is the third-generation platinum antitumor compound after cisplatin and carboplatin, and so far the only platinum-based drug with significant effectiveness against colorectal cancer. It also inhibits proliferation of ovarian cancer and melanoma cell lines.
Mechanisms of ActionActs on DNA through production of alkylating conjugates, inhibiting its synthesis and reproduction by forming interchain and intrachain cross-links.
Adverse Effects
  • Hematopoietec system: Oxaliplatin has a certain blood toxicity. When used alone, it can cause the following adverse effects: anemia, leukopenia, neutropenia, thrombocytopenia, sometimes reaching grade 3 or 4. Increases hematologic toxicities such as neutropenia and thrombocytopenia when combined with 5-fluorouracil.
  • Digestive system: can cause nausea, vomiting, and diarrhea when used alone. These symptoms can sometimes be very serious. These side effects are significantly exacerbated when used in combination with 5-fluorouacil. Use of prophylactic and/or therapeutic antiemetic drugs is recommended.
  • Nervous system: Peripheral sensory neuropathy characterized by peripheral neuritis. Sometimes associated with convulsions and sensory disturbances in the mouth, upper respiratory tract, and upper GI tract.
DescriptionOxaliplatin is a platinum-containing DNA-crosslinking agent. It induces the formation of DNA inter- and intrastrand crosslinks and DNA-protein crosslinks, inhibits DNA and RNA synthesis, and induces apoptosis in cancer cells. Oxaliplatin is cytotoxic to cisplatin-sensitive A2780(1A9) and KB-3-1 cells and cisplatin-resistant A2780-E(80) and KB-CP20 cells (IC50s = 0.12, 0.39, 4.7, and 2.7 μM, respectively). It reduces tumor growth in an HCCLM3 mouse xenograft model when administered at doses of 5 or 10 mg/kg once per week. Formulations containing oxaliplatin have been used in the treatment of advanced colorectal cancer and as an adjuvant in stage III colon cancer.
DescriptionEloxatin was launched in France for second-line treatment of metastatic colorectal cancer. Oxaliplatin is a second generation platinum drug prepared in three steps from either k2tCl4 or K2Ptl4. It has an antitumor spectrum similar to cisplatin, however, it is more effective against L1210 leukemia and cisplatin resistant L1210. It is also effective against B16 melanoma but has a dose limiting toxicity of peripheral sensory neuropathy that is reversible upon cessation of the drug. The (R,R)- enantiomer has greater activity than the (S,S)-isomer but this is tumor line dependent, e.g., there was no difference found for P-388 or Sarcoma 180. Clinical drug administration based on circadium timing showed it was better tolerated when given 16 h after the onset of light. Oxaliplatin binds to guanineN7 and can lead to bidentate chelation that results in the bending of DNA. This feature is recognized by high mobility group proteins (HMG) which impedes repair reactions and stops replication and transcription.
Chemical PropertiesWhite Crystalline Solid
OriginatorBebiopharm (Switzerland)
UsesA potent anti-neoplastic agent that binds to DNA and shows efficacy in Cisplatin resistant cell lines
UsesA antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA
UsesThird generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic.
UsesOxaliplatin is a platinum-based antineoplastic agent that functions by forming DNA adducts specifically in cancer cells, preventing DNA replication and transcription which leads to cell death. Oxaliplatin has cytotoxic effects in a broad range of cell lines, including colon, ovarian, and lung cancer, with IC50 values ranging from 0.5-240, 0.12-19.8, and 2.6-6.1 μM, respectively. Through its general cytotoxic effects, oxaliplatin has anti-tumor activity against advanced colorectal cancer and is typically administered with fluorouracil and leucovorin in a combination known as FOLFOX.
Brand nameEloxatin (Sanofi Aventis).
General DescriptionOxaliplatin is available in 50- and 100-mg vials for IV administrationin the treatment of ovarian cancer, metastaticcolorectal cancer, and early stage colon cancer in combinationwith 5-fluorouracil/leucovorin. The activation of theagent occurs in low-chloride environments to give theaquated species, which subsequently reacts with DNA in amanner similar to cisplatin. The mechanisms of resistance aresimilar for the two agents; however, oxaliplatin is not recognizedby MMR enzymes and does not show cross-resistancewith cisplatin. The agent is widely distributed, highly proteinbound (85%–88%), and irreversibly binds to erythrocytes.Numerous metabolites have been identified many of whichare produced as a result of nonenzymatic processes and includechloro-, dichloro-, monoaquo-, and diaquo-species.The parent and metabolites are eliminated primarily in theurine with a long terminal elimination half-life of 240 hours.Neurotoxicity is dose limiting and normally presents as peripheralneuropathy, which may be exacerbated by exposureto low temperatures. The neurotoxicity is normally reversiblein contrast to that seen with cisplatin, which may be irreversible.Other adverse effects include nausea, vomiting, diarrhea,myelosuppression, and hypersensitivity reactions.Ototoxicity and renal toxicity occur only rarely in contrast tocisplatin.
Biological ActivityAntitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (cis-Diaminodichloroplatinum ) and shows antitumor activity in cell lines with acquired cisplatin resistance.
Biochem/physiol ActionsOxaliplatin a platinum analogue, causes DNA damage and cell death by binding to DNA and forming inter and intrastrand crosslinks preventing replication and transcription. Oxaliplatin is an anti-tumor agent with activity against colorectal cancer; cytotoxicity follows the formation of adducts with DNA. Oxaliplatin is an approved drug for treating colorectal cancer. It is an active ingredient in FOLFOX (Folinic acid:5-FU:oxaliplatin in the ratio 1:10:1 of micromolar concentrations respectively). Oxaliplatin causes both acute and chronic neurotoxicity in patients in a dose dependent manner and is reversible either by reducing or stopping the drug.
Safety ProfileA poison by intraperitoneal route. When heated to decomposition it emits toxic vapors of NOx and Pt.
Tag:Oxaliplatin(61825-94-3) Related Product Information
Methyl D-(-)-4-hydroxy-phenylglycinate D(-)-Phenylglycinamide Oxaliplatin-d10 Oxaliplatin impurity D Carboplatin Docetaxel Cisplatin 1,2-Diaminocyclohexane Oxaliplatin OXALIPLATIN IMPURITY D Oxaliplatin for Injection OXALIPIATIN OXALIPLATIN IMPURITY C OXALIPLATIN IMPURITY B (1,2-Cyclohexanediamine)hydroxy platinum (1R,2R)-(-)-1,2-Diaminocyclohexane Nedaplatin (S)-Amlodipine